Art. 23 Directive (EU) 2001/83

In forcesince 20 Jan 2011cited 17×
1.

After a marketing authorisation has been granted, the marketing authorisation holder shall, in respect of the methods of manufacture and control provided for in Article 8(3)(d) and (h), take account of scientific and technical progress and introduce any changes that may be required to enable the medicinal product to be manufactured and checked by means of generally accepted scientific methods.

Those changes shall be subject to the approval of the competent authority of the Member State concerned.

2.

The marketing authorisation holder shall forthwith provide the national competent authority with any new information which might entail the amendment of the particulars or documents referred to in Article 8(3), Articles 10, 10a, 10b and 11, or Article 32(5), or Annex I.

In particular, the marketing authorisation holder shall forthwith inform the national competent authority of any prohibition or restriction imposed by the competent authorities of any country in which the medicinal product is marketed and of any other new information which might influence the evaluation of the benefits and risks of the medicinal product concerned. The information shall include both positive and negative results of clinical trials or other studies in all indications and populations, whether or not included in the marketing authorisation, as well as data on the use of the medicinal product where such use is outside the terms of the marketing authorisation.

3.

The marketing authorisation holder shall ensure that the product information is kept up to date with the current scientific knowledge, including the conclusions of the assessment and recommendations made public by means of the European medicines web-portal established in accordance with Article 26 of Regulation (EC) No 726/2004.

4.

In order to be able to continuously assess the risk-benefit balance, the national competent authority may at any time ask the marketing authorisation holder to forward data demonstrating that the risk-benefit balance remains favourable. The marketing authorisation holder shall answer fully and promptly any such request.

The national competent authority may at any time ask the marketing authorisation holder to submit a copy of the pharmacovigilance system master file. The marketing authorisation holder shall submit the copy at the latest 7 days after receipt of the request.

The 10 that are cited most themselves, of 17.

  • Directive (EU) 2010/84Lawamends

  • Directive (EU) 2004/27Lawamends

  • Commission Regulation (EU) No 712/2012 of 3 August 2012 amending Regulation (EC) No 1234…Law

    … 67.], en met name artikel 23 ter, lid 1, Gezien Verordening (EG) nr. 726/2004 van het Europees Parlement en de Raad van 31 maart 2004 tot vaststelling van communautaire procedures voor het verlenen van vergunningen en het toezicht op …

  • Commission Implementing Regulation (EU) No 520/2012 of 19 June 2012 on the performance o…7Law

    … За целите на член 23, параграф 4 от Директива 2001/83/ЕО националният компетентен орган може да ограничи искането си до конкретно …

  • Opinion of Advocate General Saugmandsgaard Øe delivered on 25 July 2018. Novartis Farma SpA v Agenzia Italiana del Farmaco (AIFA) and OthersDecision

    To my mind, where the repackaging in several individual doses of a medicinal product that falls within the scope of Directive 2001/83 does not involve the medicinal substance being modified, the product repackaged in that way continues to …

    25 Jul 2018 · 62017CC0029

  • Judgment of the General Court (Tenth Chamber) of 23 September 2020 (Extracts). Medac Gesellschaft für klinische Spezialpräparate mbH v EuropDecision

    Finally, after an MA has been granted, Article 23(3) of Directive 2001/83 requires the MA holder to ensure that the product information is kept up to date with, in particular, the current scientific knowledge, including the conclusions of …

    23 Sep 2020 · 62019TJ0549

  • Judgment of the Court (First Chamber) of 21 November 2018. Novartis Farma SpA v Agenzia Italiana del Farmaco (AIFA) and Others.Decision

    As regards the pharmacovigilance system for medicinal products placed on the EU market, the Court notes that, in accordance with Article 23(2) and Article 101(1) of Directive 2001/83, that system also covers any use of a medicinal product …

    21 Nov 2018 · 62017CJ0029

  • Opinion of Mr Advocate General Jääskinen delivered on 19 October 2010. Novo Nordisk AS v Ravimiamet.Decision

    According to Article 23(3) of Directive 2001/83, the holder of the marketing authorisation is forthwith to supply to the competent authority any new information which might entail the amendment of the particulars or documents referred to …

    19 Oct 2010 · 62009CC0249

  • Judgment of the General Court (Fifth Chamber, Extended Composition) of 15 May 2024. Fresenius Kabi Austria GmbH and Others v European CommisDecision

    First, Article 23(2) of Directive 2001/83, as amended, lays down certain information obligations incumbent on each holder of an MA for a medicinal product.

    15 May 2024 · 62022TJ0416

  • Regulation (EU) 2021/756Law

    … 67.], en met name artikel 23 ter, Gezien Verordening (EG) nr. 726/2004 van het Europees Parlement en de Raad van 31 maart 2004 tot vaststelling van procedures van de Unie voor het verlenen van vergunningen en het toezicht op geneesmiddelen …